home · filing · 0001193125-23-193453
8-K filed July 25, 2023, 7:59 PM ET
ticker URGN
CIK 0001668243
leadership
confidence high
sentiment neutral
materiality 0.25
UroGen appoints James A. Robinson Jr. to Board, increasing size to 9 directors
UroGen Pharma Ltd.
Board increased from 8 to 9; Robinson appointed to fill vacancy and serve on Compliance Committee.
Initial option grant of 20,000 ordinary shares, vesting quarterly over 12 quarters.
Annual retainer of $40,000 plus $5,000 for Compliance Committee service.
Eligible for annual option grant of 10,000 shares at each annual shareholder meeting.
Standard indemnity agreement will be entered with Robinson.
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Appointed
James A. Robinson Jr.
Director
URGN ·
UroGen Pharma Ltd.
Effective 2023-07-25
Filed July 25, 2023, 7:59 PM ET
appointed James A. Robinson Jr. to fill the vacancy on the Board and to hold office until the Company’s 2023 Annual Meeting of Shareholders
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
James A. Robinson Jr. was appointed as Director at UroGen Pharma Ltd..
Action appointed
Role Director
Exact text from the filing
appointed James A. Robinson Jr. to fill the vacancy on the Board and to hold office until the Company’s 2023 Annual Meeting of Shareholders
View on SEC.gov
Source: SEC EDGAR
accession 0001193125-23-193453
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.